Novel targets and approaches in advanced prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Therapeutic resistance is a primary driver of cancer mortality, particularly in advanced prostate cancer.
• Understanding resistance to androgen withdrawal and chemotherapy is crucial for developing effective treatments.

Purpose of the Study:

• To review novel treatment options for advanced prostate cancer.
• To explore the molecular basis of resistance to androgen withdrawal and chemotherapy.
• To guide the rational design of targeted therapeutics.

Main Methods:

• Review of current literature on prostate cancer progression and therapeutic resistance.
• Analysis of novel compounds and their entry into clinical trials.
• Evaluation of combination regimens targeting key cellular networks.

Main Results:

• Taxanes are current first-line agents for metastatic hormone-refractory prostate cancer, but drug resistance leads to eventual progression.
• Advances in understanding cancer progression have identified numerous gene targets regulating apoptosis, proliferation, and cell signaling.
• Numerous novel compounds are in clinical trials, used as single agents or in combination with chemotherapy.

Conclusions:

• Hormone-refractory prostate cancer remains incurable but treatable.
• Combination regimens targeting crucial cellular networks, such as the apoptotic rheostat, show promise over single-target agents.
• Further phase III trials are needed to demonstrate efficacy with survival as the primary endpoint.